Our best read stories about formularies include news about 2022 formularies from CVS Caremark and Express Scripts.
Four products on the preferred list this year will be excluded next year.
The COX-2 inhibitor Anjeso, a faster-acting injectable formulation of meloxicam, reduces opioid use after surgery.
Read more
CVS Caremark has removed 10 branded products from its formulary and added about 30 additional products.
Read more
Cigna plans to remove 45 drugs from its Standard Prescription Drug List and add restrictions for other therapeutics.
Read more
Prime’s formularies will include the insulin biosimilar over the reference product Lantus beginning in January 2022.
Read more
FDA Approves Combination Therapy for Pulmonary Arterial Hypertension
March 25th 2024J&J’s Opsynvi is single-tablet combination of macitentan, an endothelin receptor antagonist, and tadalafil, a PDE5 inhibitor. It will be priced on parity with Opsumit, which is also a J&J product to treat patients with PAH.